Novo Nordisk Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Cantor Fitzgerald Raises Price Target on Novo Nordisk to $140 From $120, Keeps Overweight Rating
Novo Nordisk Analyst Ratings
Amgen Upgraded at RBC on Catalyst Setup and Growth Drivers
TD Cowen Maintains Outperform on Novo Nordisk, Raises Price Target to $115
Novo Nordisk Analyst Ratings
Cantor Fitzgerald Initiates Coverage On Novo Nordisk With Overweight Rating, Announces Price Target of $120
Novo Nordisk Analyst Ratings
ResMed Upgraded at JPMorgan; Says GLP-1 Threat Overdone
Argus Research Initiates Coverage On Novo Nordisk With Buy Rating, Announces Price Target of $110
No Data